Highlights

  • A US National Institutes of Health grant will fully fund an Expanded Access Program for Neurizon Therapeutics’ (ASX:NUZ) lead ALS candidate, NUZ-001.
  • The program is expected to provide access to NUZ-001 for up to 200 people with ALS who are otherwise ineligible for clinical trials.
  • The EAP will run alongside the ongoing Phase 2/3 HEALEY ALS Platform Trial and generate complementary long-term safety, survival, biomarker and clinical data.
  • The development comes as incoming CEO Dr Chris Bremer prepares to lead Neurizon through an increasingly important clinical and Partnership phase.

Neurizon Therapeutics (ASX:NUZ) has added another significant component to the clinical development program for NUZ-001, with the US National Institutes of Health funding an Expanded Access Program designed to provide the investigational therapy to a broader population of people living with amyotrophic lateral sclerosis.

The multimillion-dollar, multi-year NIH grant will fund the program, including specified drug supply, manufacturing, regulatory, safety-monitoring and operational costs associated with Neurizon’s participation.

For the company, the program potentially expands clinical exposure to NUZ-001 without requiring Neurizon to fund the initiative independently. It will also generate an additional body of long-term data alongside the controlled Phase 2/3 HEALEY ALS Platform Trial.

NIH-Funded Access Program

Under the Expanded Access Protocol, up to 200 people living with ALS who are otherwise unable to participate in Clinical Trials are expected to receive access to NUZ-001 for periods of up to 96 weeks.

Expanded Access, sometimes referred to as compassionate use, allows patients with serious or life-threatening diseases to receive an investigational therapy when an appropriate clinical trial is unavailable to them.

The Sean M. Healey & AMG Center for ALS at Mass General Brigham will serve as the prime recipient of the NIH grant, while Neurizon Therapeutics (ASX:NUZ) will receive funding as a subawardee.

Responsibilities are divided between the parties.

The Healey & AMG Center will manage clinical and operational execution, including site activation, participant recruitment and data collection.

Neurizon will remain the regulatory sponsor and Investigational New Drug holder and will Supply NUZ-001 for the program.

Start-up activities are already underway, with participant enrolment targeted to begin by the first quarter of calendar 2027, subject to regulatory, site activation and operational requirements.

Broader US Access

The EAP is expected to operate through approximately 20 physical ALS clinical sites as well as a national virtual study site.

The model is intended to provide potential access across all 50 US states.

Physical locations are expected to include centres already involved in the HEALEY ALS Platform Trial, while the virtual component is designed to make participation more accessible to people living in rural or underserved regions.

That substantially broadens the potential patient population exposed to NUZ-001 compared with a conventional randomised clinical trial alone.

However, the Expanded Access Program is not itself a substitute for controlled clinical evidence.

Its role is complementary, particularly in generating long-term safety and real-world information from patients who may not meet the inclusion criteria of the main trial.

Building the NUZ-001 Data Set

The program is designed to collect safety and tolerability information along with survival data, ALS-specific functional and respiratory measures, patient-reported outcomes and exploratory biomarkers.

Measures are expected to include ALSFRS-R and slow vital capacity.

This data will sit alongside the controlled efficacy and safety information being generated through Regimen I of the Phase 2/3 HEALEY ALS Platform Trial.

NUZ-001 is currently being assessed in approximately 250 participants within that trial.

Topline results remain anticipated in late Q2 CY2027.

Importantly, continuation of the Expanded Access Program beyond those topline results is contingent upon a positive outcome from the HEALEY ALS Platform Trial.

That makes the main trial the central value-defining clinical event.

The EAP can expand exposure and strengthen the long-term safety database, but it does not reduce the importance of demonstrating efficacy in a controlled setting.

The Programme Bremer Inherits

The latest development also arrives shortly before a planned Leadership transition.

In early September 2026, Neurizon Therapeutics (ASX:NUZ) announced the appointment of Dr Chris Bremer as chief executive officer, effective 1 October 2026.

Bremer brings more than two decades of pharmaceutical and biotechnology leadership experience, including senior roles within the global pharmaceutical industry and experience in licensing transactions exceeding US$1 billion.

He will therefore assume leadership as Neurizon moves through a more complex phase involving a late-stage clinical trial, an NIH-funded access program and potential future partnering opportunities.

Neurizon, previously known as PharmAust Limited, is focused on developing NUZ-001, a formulation of S-monepantel, for ALS.

The candidate has been accepted as Regimen I within the HEALEY ALS Platform Trial, where enrolment and dosing are underway.

Funding Structure Matters

The NIH award is important because the Expanded Access Program is fully funded through the grant.

The funding framework covers EAP-related drug supply, Manufacturing and specified regulatory, pharmacovigilance, safety-monitoring and operational activities.

Neurizon has also highlighted its existing long-term supply agreement with Elanco Animal Health as supporting scalable access to the active pharmaceutical ingredient required for NUZ-001.

That reduces the direct financial burden associated with substantially increasing patient exposure.

The distinction remains important, however: NIH funding for the EAP does not mean NUZ-001 has been approved by the US Food and Drug Administration.

NUZ-001 remains an investigational product and is not approved for commercial use in any jurisdiction.

Clinical Risk Remains Central

The latest development strengthens the clinical infrastructure around NUZ-001, but it does not remove the fundamental risks associated with drug development.

ALS remains a difficult therapeutic area, and expanded patient access should not be interpreted as evidence of efficacy.

The HEALEY ALS Platform Trial remains the more important controlled assessment of whether NUZ-001 can deliver meaningful clinical benefit.

Neurizon must also continue managing the funding requirements associated with its broader development activities.

At 30 June 2026, the company reported approximately A$12.7 million in cash and total Debt of about A$3.3 million.

Its FY2026 after-tax loss narrowed to approximately A$10.72 million, while net Assets increased to around A$12.73 million.

Although the NIH-supported EAP reduces the direct cost of this additional clinical program, funding for the company’s wider operations remains an issue to monitor ahead of the anticipated 2027 trial readout.

What to Watch

The first milestone is commencement of participant enrolment into the Expanded Access Program, targeted by Q1 CY2027.

The second is how quickly the program establishes its planned network of physical and virtual sites and begins generating long-term safety and clinical data.

The third, and most important, remains the Phase 2/3 HEALEY ALS Platform Trial topline readout anticipated in late Q2 CY2027.

A positive outcome would allow the EAP to continue beyond that point and could materially influence the next stage of NUZ-001 development.

The incoming CEO transition also deserves attention. Bremer takes control at a point when Neurizon Therapeutics (ASX:NUZ) is moving beyond a single clinical-trial narrative toward a broader US clinical-development framework involving NIH funding, expanded patient access and potential future partnering activity.